Qelbree (viloxazine) can begin reducing ADHD symptoms within one to two weeks, with continued improvement over the following weeks as your dose is adjusted. In clinical trials, measurable improvements appeared by week one in children and by week two in adults, though most people don’t reach the full benefit until around week six.
That timeline feels slow compared to stimulant medications, which work within an hour of the first dose. But Qelbree is a non-stimulant, and it works through a different process that requires your brain chemistry to gradually shift. Understanding what to expect at each stage can help you stick with it long enough to see results.
What Happens in the First Two Weeks
Qelbree itself is absorbed quickly. Blood levels peak about five hours after you take a capsule, and the drug is active in your body within roughly an hour. But feeling it “work” for ADHD is a separate question. The medication raises levels of norepinephrine and, to a lesser degree, dopamine and serotonin in parts of the brain involved in attention and impulse control. Those chemical shifts need time to translate into noticeable changes in focus and behavior.
In a clinical trial of adults, ADHD symptom scores dropped significantly by the two-week mark compared to placebo. A study comparing viloxazine to other non-stimulants found that children showed improvements as early as one week. So while it’s not instant, most people aren’t waiting months for a signal that the medication is doing something.
During these first two weeks, you’re also likely on the starting dose, not the final one. Children ages 6 to 11 begin at 100 mg daily, while teens (12 to 17) and adults start at 200 mg daily. Your prescriber will increase the dose in weekly steps based on how you respond. That gradual ramp-up means the medication’s full strength hasn’t kicked in yet during week one or two.
When Qelbree Reaches Full Effect
The clearest picture comes from a six-week trial in adults. By week six, 60% of people taking Qelbree achieved at least a 30% reduction in ADHD symptoms, compared to 48% on placebo. About 39% hit a 50% reduction, a threshold that represents a more substantial, day-to-day noticeable change. Symptom scores continued improving at each follow-up visit from week two through the end of the study, and executive function (things like planning, organizing, and managing time) also improved by week six.
This means the medication doesn’t simply “turn on” at a fixed point. It builds. You may notice modest improvements early, with more meaningful changes accumulating over the first four to six weeks as your dose reaches its target and your brain adjusts.
How the Dose Ramp-Up Affects the Timeline
Because Qelbree is titrated weekly, the timeline to full effect partly depends on how quickly your dose reaches the right level. Here’s what that looks like for each age group:
- Children (6 to 11): Start at 100 mg daily. Dose increases by 100 mg each week, up to a maximum of 400 mg. Reaching the top dose takes about four weeks.
- Teens (12 to 17): Start at 200 mg daily. Can increase to 400 mg after one week. Some teens reach their target dose within one to two weeks.
- Adults: Start at 200 mg daily. Dose increases by 200 mg each week, up to a maximum of 600 mg. Reaching the highest dose takes about three weeks.
Not everyone needs the maximum dose. Some people respond well at a lower level, which can shorten the overall timeline. Others need the full amount and won’t see the complete picture until they’ve been at that dose for a couple of weeks.
Side Effects During the Adjustment Period
The first few weeks on Qelbree often come with temporary side effects that can make it harder to judge whether the medication is working. Drowsiness, fatigue, reduced appetite, and sleep problems are common early on. For many people, these fade within days to a few weeks as the body adjusts.
One side effect that requires closer attention is a potential increase in suicidal thoughts or behaviors, which the FDA highlights in a boxed warning. This risk is highest when starting treatment or changing doses. It doesn’t mean the medication causes these thoughts in most people, but it’s the reason prescribers monitor patients closely during the early weeks, especially children and teens. Increases in heart rate and blood pressure can also occur and are typically checked at each dose change.
Sleepiness and fatigue during the first week or two sometimes lead people to assume the medication isn’t helping their focus. In many cases, those sedating effects settle down while the attention benefits continue to build.
How This Compares to Stimulants
Stimulant medications like methylphenidate and amphetamines work within 30 to 60 minutes and wear off the same day. You know on day one whether they’re helping. Qelbree doesn’t offer that kind of immediate feedback, and that’s a common source of frustration for people switching from stimulants or trying ADHD medication for the first time.
The tradeoff is that Qelbree carries no risk of abuse, doesn’t typically suppress appetite as severely, and is less likely to worsen anxiety, mood issues, or tics. For people who can’t tolerate stimulants or prefer a non-stimulant option, the slower onset is part of a different risk-benefit balance. The key is giving it a genuine trial of at least four to six weeks at an adequate dose before deciding it isn’t working.
What to Track While You Wait
Because Qelbree’s effects are gradual, it’s easy to miss improvements that build slowly. Keeping a simple daily log can help. Note things like how many times you lost focus during work or school, whether you finished tasks you started, how impulsive you felt, and how your energy and mood were throughout the day. Reviewing a few weeks of entries often reveals patterns that aren’t obvious in the moment.
If you’ve been on a stable dose for four to six weeks and see no meaningful change in your symptoms, that’s useful information for your prescriber. It may mean the dose needs to go higher, or that Qelbree isn’t the right fit. What it doesn’t mean is that all non-stimulant options have failed, since people respond differently to different medications in this class.